14-3-3 family members are dimeric phosphoserinebinding proteins that regulate signal transduction, apoptotic, and checkpoint control pathways. Targeted expression of dominant-negative 14-3-3 (DN-14-3-3) to murine postnatal cardiac tissue potentiates Ask1, c-jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) activation. DN-14-3-3 mice are unable to compensate for pressure overload, which results in increased mortality, dilated cardiomyopathy, and cardiac myocyte apoptosis. To evaluate the relative role of p38 MAPK activity in the DN-14-3-3 phenotype, we inhibited cardiac p38 MAPK activity by pharmacological and genetic methods. Intraperitoneal injection of SB202190, an inhibitor of p38␣ and p38␤ MAPK activity, markedly increased the ability of DN-14-3-3 mice to compensate for pressure overload, with decreased mortality. DN-14-3-3 mice were bred with transgenic mice in which dominant-negative p38␣ (DN-p38␣) or dominantnegative p38␤ (DN-p38␤) MAPK expression was targeted to the heart. Compound transgenic DN-14-3-3/DNp38␤ mice, and to a lesser extent compound transgenic DN-14-3-3/DN-p38␣ mice, exhibited reduced mortality and cardiac myocyte apoptosis in response to pressure overload, demonstrating that DN-14-3-3 promotes cardiac apoptosis due to stimulation of p38 MAPK activity.
1
4-3-3 proteins are intracellular phosphoserine-binding adapter molecules. 1,2 14-3-3 proteins modulate several important signal transduction, apoptotic, and checkpoint control pathways by binding to many signaling proteins, including the protein kinases Ask1 3 and Raf-1. 4 Ask1 is a mitogenactivated protein kinase kinase kinase (MAPKKK) that participates in the c-jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways. 5 14-3-3 binding to Ask1 inhibits its enzymatic activity. 3, 6 Previously, we investigated the biological effects of 14-3-3 proteins in cultured cells and in transgenic animals by use of dominant-negative forms of 14-3-3 (DN14-3-3). 6 DN-14-3-3-transfected fibroblasts exhibited increased Ask1, p38 MAPK, and JNK activities. Inhibition of 14-3-3 activity also caused cultured cells to become sensitized to proapoptotic stimuli, including UV irradiation and serum deprivation. The proapoptotic effect of DN-14-3-3 in fibroblasts was blocked by treatment with the p38 MAPK inhibitor SB202190.
Transgenic mice were generated with cardiac-specific overexpression of DN-14-3-3. 6 These mice appeared normal at baseline but were unable to compensate for pressure overload induced by transverse aortic constriction (TAC), a mild stimulus of cardiac myocyte apoptosis. DN-14-3-3 mice tolerated TAC poorly and most animals died from overwhelming cardiac dysfunction. TUNEL studies revealed that there was massive cardiac myocyte apoptosis in DN-14-3-3 ventricular tissue but not in nontransgenic cardiac tissue after TAC. To evaluate the importance of p38 MAPK activation in the DN-14-3-3 phenotype, we inhibited cardiac p38 MAPK activity by pharmacological and genetic methods in the present work.
Materials and Methods
Transgenic mice with cardiac-specific expression of DN-14-3-3 were evaluated in this work. 6 DN-14-3-3 mice were subjected to pressure overload by TAC in the presence or absence of intraperitoneal administration of SB202190, 5 mg · kg Ϫ1 · d Ϫ1 , a chemical inhibitor of p38␣ and p38␤ MAPK. Next, DN-14-3-3 mice were bred with transgenic mice in the same strain that had cardiac-specific expression of dominant-negative forms of p38␣ MAPK (DN-p38␣) or p38␤ MAPK (DN-p38␤) to generate compound transgenic DN-14-3-3/DN-p38␣ or DN-14-3-3/DN-p38␤ mice. 7 Compound transgenic mice were also subjected to pressure overload by TAC, and survival, MAPK activation, and apoptosis were assayed by conventional methods.
An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.
Results
An experimental protocol to administer SB202190, a specific inhibitor of p38␣ and p38␤ MAPK, was established in DN-14-3-3 transgenic mice. In this method, SB202190 was delivered daily by intraperitoneal injection, beginning 3 days before TAC. After 10 days of administration (7 days after TAC), ventricular tissue was isolated and cytosolic protein lysates were generated. Anti-p38 MAPK immunoprecipitates from these lysates were produced with an antibody that recognizes both p38␣ and p38␤ MAPK. Immunoprecipitations were assayed for p38 MAPK enzymatic activity by in vitro kinase assay with recombinant ATF-2 protein used as a substrate. In vitro kinase assays demonstrated that daily administration of 5 mg/kg of SB202190 inhibited p38 MAPK activity in cardiac tissue ( Figure 1A ). In addition, analysis of protein lysates by anti-phospho-HSP27 immunoblotting demonstrated that SB202190 treatment blocked cardiac phosphorylation of HSP27, a well-defined substrate of p38 MAPK (data not shown). To determine whether inhibition of p38 MAPK activity could block the DN-14-3-3 phenotype, we performed a series of TAC experiments. DN-14-3-3 mice that were injected with control buffer did not tolerate TAC and only 21% of animals survived (6 of 29) for 7 days after the surgical procedure. In contrast, 82% of animals (9 of 11) treated with SB202190 for 3 days before TAC survived for at least 7 days after surgery ( Figure 1B) . The difference in survival observed in SB202190-treated DN-14-3-3 mice was significant by the Kaplan-Meier log-rank test ( 2 ϭ11.0, Pϭ0.0009). To specifically determine which p38 MAPK isoform was important for the abnormal response of DN-14-3-3 mice to TAC, transgenic mice with cardiac-specific expression of DN-p38␣ and DN-p38␤ were bred with DN-14-3-3 mice. 7 DN-14-3-3 protein levels were not altered in compound transgenic DN-14-3-3/DN-p38␣ and DN-14-3-3/DN-p38␤ compared with single transgenic DN-14-3-3 mice (Figure 2) . We previously demonstrated that DN-p38␣ mice exhibit reduced p38␣ MAPK activation and that DN-p38␤ transgenic mice exhibit reduced p38␤ MAPK activation in cardiac tissue. 7 TAC experiments were performed on transgenic mice and, in each case, compound transgenic mice were compared with single transgenic DN-14-3-3 littermates and nontransgenic littermates. As expected, single transgenic DN-14-3-3 mice were intolerant to pressure overload and only 6% of mice (1 of 17) survived for 7 days after TAC. In contrast, DN-14-3-3/DN-p38␤ mice were completely resistant to TAC-induced death and 100% of animals (10 of 10) survived. The difference in survival observed in compound transgenic DN-14-3-3/DN-p38␤ mice compared with single transgenic DN-14-3-3 mice was significant by the log-rank test ( 2 ϭ16.6, PϽ0.0001). DN-14-3-3/DN-p38␣ mice were partially resistant to TAC-induced death and 60% of animals (9 of 15) mice survived ( Figure 2) . The difference in survival observed in compound transgenic DN-14-3-3/DN-p38␣ mice compared with DN-14-3-3 mice was significant by analysis with the log-rank test ( 2 ϭ7.1, Pϭ0.008). p38 MAPK promotes apoptosis in certain cell types and this may be due to direct phosphorylation of p53 or other effectors. In response to pressure overload, we previously demonstrated that DN-14-3-3 mice develop overwhelming cardiac myocyte death. 6 Apoptosis in cardiac tissue was assessed in the present study by caspase-3 cleavage assays that confirmed that both DN-14-3-3/DN-p38␤ and DN-14-3-3/DN-p38␣ cardiac tissue had reduced apoptosis 7 days after TAC compared with DN-14-3-3 single transgenic mice (Figure 3) . The percentage of left ventricular cardiac myocytes that were immunoreactive for cleaved caspase-3 7 days after TAC was 4.2Ϯ0.93% for DN-14-3-3 mice, 0.049Ϯ0.012% for DN-14-3-3/DN-p38␤ mice, and 0.19Ϯ0.067% for DN-14-3-3/DN-p38␣ mice, and 0.045Ϯ0.015% for nontransgenic mice. A, DN-14-3-3 protein levels in cardiac tissue from single transgenic DN-14-3-3 mice or from compound transgenic DN-14-3-3/DN-p38␣ or DN-14-3-3/DN-p38␤ mice. The 14-3-3 transgenic construct contained a myc-1 epitope tag. Cytosolic lysates derived from left ventricular tissue were analyzed by immunoblotting with an anti-myc-1 epitope primary antibody (top) and an anti-pan-14-3-3 primary antibody (middle). Bottom, anti-ERK immunoblot to control for protein loading. B, Kaplan-Meier survival curves for DN-14-3-3 single transgenic, DN-14-3-3/DNp38␣ double transgenic, or DN-14-3-3/DN-p38␤ double transgenic mice subjected to TAC.
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Role of 14-3-3 and p38 MAPK in Cardiac ApoptosisDiscussion 14-3-3 proteins bind to a variety of signal transduction, checkpoint control, and apoptotic pathway proteins. 1,2 14-3-3 binding to BAD and FKHRL1 inhibits the proapoptotic activity of these proteins, thereby promoting cell survival. 8, 9 14-3-3 proteins also bind to and inhibit the activity of Ask1, a MAPKKK in the p38 MAPK and JNK pathways. 3 We previously demonstrated that inhibition of 14-3-3 activity in cultured fibroblasts promoted apoptosis in a p38 MAPKdependent fashion. 6 We also showed that dominant-negative 14-3-3 increased the sensitivity of cardiac tissue to proapoptotic stimuli. 6 In the present study, we addressed the role of p38 MAPK in the phenotype observed in DN-14-3-3 transgenic mice by both pharmacological and genetic means. Our results show that 14-3-3-mediated p38 MAPK inhibition is a critical factor to promote cardiac myocyte survival and suggest that p38␤ MAPK plays a more important role than p38␣ MAPK in the apoptosis response. But, we cannot rule out the possibility that each DN-p38 MAPK protein inhibits the other isoform to some degree. Several other studies demonstrated that p38 MAPK activity leads to cardiac myocyte apoptosis. For example, one group found that doxorubicin-and tumor necrosis factor-␣ (TNF-␣)-dependent murine cardiac myocyte apoptosis was dependent on p38 MAPK activation. 10, 11 Another group showed that hypoxia-, angiotensin II-, and norepinephrine-mediated canine cardiac myocyte apoptosis is dependent on p38 MAPK activity. 12 The specific targets of p38 MAPK that are important for a proapoptotic response are not completely known but may include the transcription factor p53. It is not clear whether p38 MAPK-mediated p53 phosphorylation is important in cardiac myocyte apoptosis, but our results suggest that inhibition of p38 MAPK in human patients may be a useful method to ameliorate cardiac myocyte death in response to provocative stimulation such as ischemia or pressure overload. Figure 3 . p38 MAPK activity required for caspase-3 activation after pressure overload. Nontransgenic, single transgenic DN-14-3-3, compound transgenic DN-14-3-3/DN-p38␣, or compound transgenic DN-14-3-3/DN-p38␤ mice were subjected to TAC and survivors were killed after 7 days. Ventricular sections were analyzed by immunohistochemistry with a primary antibody directed against cleaved (activated) caspase-3. A, Prominent anti-activated caspase-3 immunoreactivity, demarcated by brown nuclear staining, in left ventricular tissue from DN-14-3-3 mice. B, Minimal anti-activated caspase-3 immunostaining in ventricular tissue from compound transgenic DN-14-3-3/DNp38␣ mice. Minimal anti-activated caspase-3 immunostaining was also observed in DN-14-3-3/DN-p38␤ mice (data not shown).
